Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Katelyn L. Donahue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9535-9275; OpenAlex author ID A5034791030; NIH RePORTER profile ID 16165194. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
1
Labs led
0
Collaborators
40
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers, 1 grant · 2025: 1 paper · 2026: 2 papers

Papers 11

  1. Aryl Hydrocarbon Receptor Ligands Drive Pancreatic Cancer Initiation and Progression through Protumorigenic T-cell Polarization. Co-author DOI 10.1158/2159-8290.cd-25-0377↗
  2. Targeting CCR1 Remodels the Tumor Microenvironment and Relieves Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1300↗
  3. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  4. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  5. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  6. WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer. Co-author DOI 10.1084/jem.20220503↗
  7. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Co-author DOI 10.7554/elife.80721↗
  8. Hypoxia promotes an inflammatory phenotype of fibroblasts in pancreatic cancer. Co-author DOI 10.1038/s41389-022-00434-2↗
  9. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  10. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  11. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗

Grants 1

  1. Regulation and role of fibroblast-derived interleukin-33 in the pancreatic tumor microenvironment F31CA265085↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen S. Carpenter · 11 shared papers, 2020–2026 · strength 1.65
  2. Marina Pasca di Magliano · 11 shared papers, 2020–2026 · strength 1.65
  3. Filip Bednar · 8 shared papers, 2020–2026 · strength 1.22
  4. Padma Kadiyala · 6 shared papers, 2023–2026 · strength 1.05
  5. Timothy L. Frankel · 6 shared papers, 2020–2026 · strength 0.91
  6. Rosa Elena Menjivar · 5 shared papers, 2021–2026 · strength 0.78
  7. Samantha B. Kemp · 6 shared papers, 2020–2025 · strength 0.77
  8. Nina G. Steele · 6 shared papers, 2020–2025 · strength 0.77
  9. Yaqing Zhang · 4 shared papers, 2023–2026 · strength 0.76
  10. Howard C. Crawford · 6 shared papers, 2020–2025 · strength 0.75
  11. Ahmed M. Elhossiny · 4 shared papers, 2024–2026 · strength 0.74
  12. Zeribe C. Nwosu · 5 shared papers, 2021–2026 · strength 0.67
  13. Wenting Du · 4 shared papers, 2023–2024 · strength 0.61
  14. Costas Andreas Lyssiotis · 5 shared papers, 2020–2026 · strength 0.61
  15. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  16. Vaibhav Sahai · 4 shared papers, 2020–2025 · strength 0.49
  17. Emily L. Lasse Opsahl · 2 shared papers, 2025–2026 · strength 0.39
  18. Wei Yan · 2 shared papers, 2024–2026 · strength 0.37
  19. Yaqing Zhang · 3 shared papers, 2021–2023 · strength 0.34
  20. Jiaqi Shi · 2 shared papers, 2024–2025 · strength 0.32
  21. Benjamin Allen · 2 shared papers, 2020–2025 · strength 0.26
  22. Holly Attebury · 1 shared paper, 2026 · strength 0.22
  23. Brian D. Griffith · 1 shared paper, 2026 · strength 0.22
  24. Michelle Ann Anderson · 2 shared papers, 2020–2024 · strength 0.20
  25. Dominik Awad · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.